UCB SA struck a licensing agreement with Antengene for ATG‑201, a CD19/CD3 bispecific T‑cell engager (TCE) aimed at autoimmune indications, in a deal valued at up to $1.1 billion plus near‑term payments. UCB will take exclusive global rights to develop, manufacture and commercialize the candidate and its manufacturing know‑how. Antengene will complete planned first‑in‑human Phase I studies before transferring the program; the agreement includes roughly $80 million in up‑front and near‑term milestones and tiered downstream payments tied to development and commercial milestones. UCB framed the transaction as a strategic entry into TCE modalities for immunology, complementing its existing biologics portfolio and signaling Big Pharma’s continued appetite to buy or license early bispecific platforms from Asia‑based developers. For investors and R&D teams: the deal highlights industry momentum behind bispecific T‑cell engagers beyond oncology and reinforces the commercial pathway for Asia‑discovered biologics to be advanced by Western pharma through licensing and upfront capital.